A Prospective Observational Study to Assess the Efficacy of a SGLT2 Inhibitor (Dapagliflozin) in Kidney Allograft Recipients with Diabetes Mellitus

被引：0
|
作者：
Naskar, Avishek [1 ]
机构：
[1] Kolkata Kidney Inst, Kolkata, West Bengal, India
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2024年 / 35卷 / 10期
关键词：
D O I：
10.1681/ASN.2024ej3cxwcq
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
TH-PO741
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Treatment with SGLT2 inhibitor dapagliflozin for non-alcoholic steatohepatitis patients complicated with type 2 diabetes mellitus
    Tobita, Hiroshi
    Sato, Shuiti
    Miyake, Tatuya
    Yazaki, Tomotaka
    Isoda, Kazuki
    Mishiro, Tuyoshi
    Ishihara, Shunji
    Kinoshita, Yoshikazu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 388 - 388
  • [22] Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes
    Nakamura, Yuta
    Nagai, Yoshio
    Terashima, Yuko
    Nishine, Ami
    Ishii, Satoshi
    Kato, Hiroyuki
    Ohta, Akio
    Tanaka, Yasushi
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (17) : 2553 - 2559
  • [23] Predictors of Kidney Function Outcomes and Their Relation to SGLT2 Inhibitor Dapagliflozin in Patients with Type 2 Diabetes Mellitus Who Had Chronic Heart Failure
    Tetiana A. Berezina
    Ivan M. Fushtey
    Alexander A. Berezin
    Sergii V. Pavlov
    Alexander E. Berezin
    Advances in Therapy, 2024, 41 : 292 - 314
  • [24] Predictors of Kidney Function Outcomes and Their Relation to SGLT2 Inhibitor Dapagliflozin in Patients with Type 2 Diabetes Mellitus Who Had Chronic Heart Failure
    Berezina, Tetiana A.
    Fushtey, Ivan M.
    Berezin, Alexander A.
    Pavlov, Sergii V.
    Berezin, Alexander E.
    ADVANCES IN THERAPY, 2024, 41 (01) : 292 - 314
  • [25] Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
    Kaushal, Shaveta
    Singh, Harmanjit
    Thangaraju, Pugazhenthan
    Singh, Jasbir
    NORTH AMERICAN JOURNAL OF MEDICAL SCIENCES, 2014, 6 (03) : 107 - 113
  • [26] SGLT2 Inhibitor, an Agent for Diabetes, Heart, Kidney ... and Stroke
    Yang, Taeil
    Lee, Jooyeon
    Oh, Jaewon
    KOREAN CIRCULATION JOURNAL, 2024, 54 (09) : 562 - 564
  • [27] Exposure-efficacy outcome modeling for dapagliflozin, an orally selective SGLT2 inhibitor, in patients with type 2 diabetes
    Feng, Yan
    Zhang, Liping
    List, James F.
    Pfister, Marc
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1114 - 1114
  • [28] The SGLT2 inhibitor dapagliflozin improves kidney function in glycogen storage disease XI
    Trepiccione, Francesco
    Iervolino, Anna
    D'Acierno, Mariavittoria
    Siccardi, Sabrina
    Costanzo, Vincenzo
    Sardella, Donato
    De La Motte, Luigi R.
    D'Apolito, Luciano
    Miele, Antonio
    Perna, Alessandra F.
    Capolongo, Giovanna
    Zacchia, Miriam
    Frische, Sebastian
    Nielsen, Rikke
    Staiano, Leopoldo
    Sambri, Irene
    De Cegli, Rossella
    Unwin, Robert
    Eladari, Dominique
    Capasso, Giovambattista
    SCIENCE TRANSLATIONAL MEDICINE, 2023, 15 (720)
  • [29] The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus
    Leng, Weiling
    Wu, Mingxia
    Pan, Hang
    Lei, Xiaotian
    Chen, Liu
    Wu, Qinan
    Ouyang, Xinshou
    Liang, Ziwen
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (18)
  • [30] DAPAGLIFLOZIN, A SELECTIVE SGLT2 INHIBITOR, IMPROVED GLYCEMIC CONTROL OVER 2 WEEKS IN PATIENTS WITH TYPE 1 DIABETES MELLITUS
    Kasichayanula, S.
    Griffen, S. C.
    Chalamandaris, A.
    LaCreta, F.
    Boulton, D. W.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S19 - S20
12345